Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 14/20 | 0.67 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607922 | 0.90 | SCD (0.81) | SCDSCD5HRH3 | |
| SCHEMBL3608752 | 0.87 | SCD (0.57) | SCDSCD5 | |
| SCHEMBL31757165 | 0.83 | SCD (0.55) | SCDHRH3NPC1RAB9AKMT2A | |
| SCHEMBL4498412 | 0.81 | SCD (0.61) | SCDSCD5 | |
| SCHEMBL31162618 | 0.80 | SCD (0.52) | SCDHRH3NPC1RAB9AKMT2A | |
| SCHEMBL3601426 | 0.80 | RAB9A (0.57) | HRH3NPC1RAB9AKMT2A | |
| SCHEMBL3611004 | 0.78 | SCD (1.00) | SCDSCD5 | |
| SCHEMBL3602572 | 0.78 | SCD (0.78) | SCDSCD5HRH3 | |
| SCHEMBL3607926 | 0.77 | SCD (0.69) | SCDSCD5 | |
| SCHEMBL3607557 | 0.77 | HRH3 (0.54) | HRH3NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | SCD 1/4885SCD5 2/4885HRH3 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.